Annals of Oncology

@Annals_Oncology · joined 04 Jun 2009

Medical oncology journal with a specific interest on targeted agents, immune therapies, personalised medicine, molecular pathology, bioinformatics, and more.

52 360Followers

555Following

4 421Posts total

13.5KViews on collected posts

Postingan terbaru

Annals of Oncology@Annals_Oncology18 Sep

🆕 review in press: Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer @BianchiniGP @LLicata88 @hoperugo @CarmenCriscit @KalinskyKevin @AnnPartridgeMD @matteolambe @jhaveri_komal Read more: https://t.co/zXuGbdS1Dh h

1.5K views · 13 likes · 7 reposts · 1 replies Open on X →

Annals of Oncology@Annals_Oncology14 Sep

🆕Safety and antitumor activity of the first-in-class EGFR–HER3 bispecific antibody–drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study https://t.co/a0nk8j3zFS https://t.co/CjSv5ub1tA

2.4K views · 10 likes · 6 reposts · 1 replies Open on X →

Annals of Oncology@Annals_Oncology8 Sep

🔥SKYSCRAPER-07 phIII in unresectable ESCC after definitive CRT: 👉Atezo + tiragolumab did not improve PFS or OS vs placebo. 👉Atezo alone showed an intriguing signal: PFS 29.1 vs 16.6 m; HR 0.74, OS HR 0.69. 👉Formal testing of atezo was precluded by the hierarchical design. 2.6K views · 11 likes · 4 reposts · 2 replies Open on X →

Annals of Oncology@Annals_Oncology8 Sep

👉Another disappointing result for TIGIT, following negative ph III signals across NSCLC, SCLC, melanoma and gastroesophageal cancer. 👉PD-(L)1 consolidation after dCRT remains an interesting avenue, but the role of TIGIT looks uncertain. Read more: https://t.co/GqpU4UipoT https://

538 views · 2 likes · 2 reposts · 1 replies Open on X →

Annals of Oncology@Annals_Oncology4 Sep

🔥Now out in @Annals_Oncology the updated results from the OlympiA trial 👉With 6.1 years of median follow-up, adjuvant olaparib confirms sustained benefit in IDFS, DDFS and OS Read more: https://t.co/t3kkkPeDpZ https://t.co/gdiZgn4cD7

6.5K views · 44 likes · 20 reposts · 1 replies Open on X →

Annals of Oncology@Annals_Oncology30 Apr 2020

Stay up to date with the very latest from Annals of Oncology. Register for free to receive content and issue alerts by e-mail https://t.co/ZiMu8SiR5l or subscribe to our RSS https://t.co/tzInSj4Aed 0 views · 54 likes · 11 reposts · 17 replies Open on X →

Dibandingkan akun berukuran sama

5 postingan dari 90 hari terakhir, dibandingkan dengan rentang 10K–100K pengikut. jangkauan biasa untuk ukurannya, reaksi lebih lemah dari kebanyakan.

Median tayangan2 433akun ini997median untuk 10K–100K

Jangkauan, %4.65%akun ini3.84%median untuk 10K–100K

Interaksi, %0.93%akun ini1.52%median untuk 10K–100K

Metrik	Akun ini	Median untuk 10K–100K	Rasio
Median tayangan per postingan	2 433	997	2.44×
Jangkauan (tayangan ÷ pengikut)	4.65%	3.84%	1.21×
Tingkat interaksi	0.93%	1.52%	0.61×

Akun lain pada rentang ini → Bandingkan dengan akun lain → Bagaimana tolok ukur ini disusun →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

6.5K4 Sep

5388 Sep

2.6K

2.4K14 Sep

1.5K18 Sep

Last 5 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

1.01%4 Sep

0.93%8 Sep

0.66%

0.70%14 Sep

1.43%18 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes55.9%80 in total

Reposts27.3%39 in total

Replies4.2%6 in total

Bookmarks12.6%18 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.